ISSN 2349-7203

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals

HUMAN

Human Journals
Review Article
January 2022 Vol.:23, Issue:2

Formulation Evolution of Co-Process Excipient

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Jayashri B. Pandhare[1], Shyamlila B. Bavage[2], Qureshi S.I[3], Wakade S.L.[4]

[1]B. Pharmacy Final Year Student, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist. Latur-413512, Maharashtra, India

[2]Department of Pharmacognosy, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist. Latur-413512Maharashtra, India

[3]Department of Pharmaceutics, Latur College of Pharmacy Hasegaon, Tq. Ausa, Dist. Latur-413512 Maharashtra, India

[4]Department of Pharmaceutics,Latur college of pharmacy Hasegaon,Tq.Ausa,Dist.Latur-413512 Maharashtra, India

Submitted: 21 December 2021
Accepted: 26 December 2021
Published: 30 January 2022

Keywords: Co- processed excipient, spray drying, microcrystalline cellulose, mannitol, disintegration time, direct compression

ABSTRACT

Excipient processed excipients are formed by Spray suspension. In Mostly used in the spray drying method, Microcrystalline cellulose: Mannitol: Banana Powder dehydrated in varying degrees (30:60:10, 20:70:10, 15:75:10, and 10:80:10) were used. Advanced Excipient testing is performed using these features pressure indicator (Carr index), trusted congestion, bulk density, Hausner rate, and flow properties (Repose angle) compared to the visible mixture of auxiliary substances. The angle of Disposal of auxiliary processed compounds found to be < 30° which means good flow compared The body composition of auxiliary substances, due to Micronization, is determined by the normal particle size, Carr's index is available at 9.00-12.30%, and the Hausner rating in the range of 1.00-1.14. The placebo tablets for granules that have been processed together are formulated and tests are performed using hardness, durability, and time of dispersion. Different line modifications were used to improve models of complexity statistics, Carr index, and dispersion time. The jointly excised excipient has gotten more attention in refining the form of multiple doses, especially the tablet formation in the form of direct pressure. It can be defined in such a way that it is inclusive two or more excipients are established by the appropriate process. Collaborative analysis of excipients gives us to lead in the construction of excipients with high structures compared to light body a combination of their component. direct pressure is the preferred method of preparing the pills. Switching to direct stress and high-speed production has forced the profit industry to look for new aids. The charity industry, which has been an extension of the food industry, has embraced the use of novel biomedical and material science novels to pave the way for a new phase of co-operative aids called co-processed excipients. Co-processing is a widely researched method for preparing adjuvants that are directly suppressed because they are expensive and can be prepared indoors based on the required performance. Advanced pills have been physically tested parameters such as weight similarity, thickness, hardness, firmness, and testing. *In vitro* dissolution research ensures that the formulated formulation using a jointly processed aid indicates a continuous drug release. The configuration of the optimized tablet was noted by DSC, FTIR, and PXRD confirming the absence of any chemical changes during co-processing. The improved construction was reserved for a six-phase stability study according to ICH guidelines and was found to be stable. *In vivo* pharmacokinetic study of the optimized formation of mice exhibited the same pharmacokinetic behavior as observed in marketing Mark. (1, 2, 3, 4)

INTRODUCTION:

The biggest problem with pills and capsule production comes from the flow structures of things that should be pressed. In various operations, the excipient fullness is high (70 %) in addition to the concentration of the active substance of the drug. Direct pressure (DC) method most The pharmaceutical industry for the manufacture of antidepressants. This is production method by compression directly provides a fast and easy method that provides an effective as well successful tablet production. DC involves the preparation of a simple active body mixture herbal ingredients and auxiliary ingredients are also used in this mixture as well as their own pressure, without additional processing steps. The resources analyzed collectively were made by the granulation technique. A combination of a drug and aids that have been processed together is designed as a tablet in the form of direct pressure. for hydrophobic drug compression direct method is widely used how to integrate it into tablet volume forms. direct use The congestion method of the tablet manufacturing process reduces the cost of the integration process by a decrease in the number of steps involved in repairing a tablet. The direct pressure method is most affected by the characteristics of the powder are the ability to flow (resting angle), compression (Carr's index), and purification power. The collectively excised excipient received extra attention from a formulation of different dosage forms such as a tablet, capsule, powder, cream, oils, etc. Herbal ingredients are anything other than active medicine Part of the product integration process has been properly tested for safety and is included in the drug delivery system to any need for processing system during production or protection, support or improve stability, bioavailability, or patient acceptance or assistance in identifying or increasing productivity any other contribution to the safety and efficacy of a drug product during storage and once use. (5, 6, 7, 8, 9, 10)

PRINCIPLE OF CO-PROCESSED EXCIPIENT:

Solid substances are divided into three levels of solid-state: molecule, particles, and mass. These levels are closely linked, if the changes at one level occur the same change manifests themselves to another degree. The level of cells consists of the arrangement of certain molecules in a crystal lattice also includes events such as polymorphism, pseudopolymorphism, and amorphous state. Particle level includes the characteristics of individual particles such as shape, size, surface area, and porosity. The bulk level is made up of a unit of particles and structures such as flow, pressure, and dilution power, all of these are important elements in the structure of auxiliary materials. Because this interdependence

between each level provides a scientific framework for innovation development improve the version of existing assistants and new combinations of existing assistants. The basic solid-state of particles such as morphology, particle size, composition, surface area, porosity, and congestion affects excipient function i.e. flow, cohesion, purification capacity, scattering power, and lubricating power. Therefore, the construction of a new excipient is appropriate to start with the right particle design to deliver the functions you want. However, particle single-receiver engineering can only provide a limited amount of performance improvement. The broadest scope for excipient performance fraud is provided by collaborative processing or engineering of two or more auxiliary particles available. Co-processing is based on the concept of the novel of two or more interactive components at the level of a small particle, the main purpose of joint processing is to provide co-operative performance enhancement and conceal undesirable properties of individual excipients. The availability of a high number of collaborative processing assistants ensures many opportunities to produce "designer accessories" designed to handle specific task requirements. (11, 12, 13, 14, 15 , 16, 17)

1. Standard Excipients:

Defined as compensation or non-compensatory or excipients are shared collectively. It may contain other elements that include the corresponding components, residual processing equipment, and/or supplements. (19)

2. Mixed Excipient:

A mixed excipient is defined as a simple mixture of two or more compensatory substances or optional excipients are produced using a low-to-medium shear process in which each component is mixed but remains a combination of different chemicals, i.e. environment the parts have not been chemically altered. Mixed auxiliary substances can be solid or liquid. (19)

3. Co-processed Excipients:

A collectively excised excipients is a combination of two or more betrayal or non-compulsory items excipients are designed with modified physical design so that we can easily achieve them physical mixing and without significant chemical changes. Different coprocessing methods can be used, which include standard unit functions such as granulation, spray drying, melting solution, grinding, etc. The choice of a particular application will

depend on the materials used, their form (e.g. whether dry powders or liquids), and desirable material. Similarly, parts sizes may vary depending on the performance you want(19).

Table No. 1: Various particle properties influencing excipient functionality(28)

Particle property	Excipient functionality
Enlargement of particle size	Flowability,compressbility
estricting particle size distribution	Segregation potency
Enlargement of particle porosity	Compressibility, solubility
Surface roughness	Flowability, Segregation potency

Table No. 2: Co-processed directly compressible excipients(19)

Sucrose 3%, dextrin Microcrystalline cellulose, silicon dioxide	Dipac Prosolv	Penwest pharmaceuticals company	Directly compressible, Better flow, reduce sensitivity to wetgranulation, better hardness of tablet, reduced friability
Microcrystalline cellulose, guar gum	Avicelce 15	Fmc corporation	Less grittiness, minimal chalkiness
Calcium carbonate, sorbitol	Formaxx	Merck	Controlled particle size distribution
Microcrystalline cellulose, lactose	Microlela	Meggle	Capable of formulating high dose, small tablets with poorly flowableactive ingredients

METHODS:

1. True density –

The actual powder density is measured with the help of a helium pycnometer 1305 (Micromeritics, Norcross, GA, USA), and the required amount of powder for each measure is about 3 g. Estimates were made three times per sample. (20)

2. Particle Size Distribution –

The distribution of particle size in all powders is determined by the separation of the dry laser (Mastersizer 2.18; Malvern Instruments Ltd, Malvern, United Kingdom). Powder-made samples were separated by pressure of 0.4 bars, and the feed level was adjusted to 1.8. Each measure was produced at least three times and the diameter of the central particles was the same used to specify particle size. (20)

3. Tapped and Bulk Density –

Reliable (ρT) and mass (ρB) are rated according to the method described in European Pharmacopoeia. Their determination allowed us to calculate Carr's (C) index once Hausner

(H) rating in terms of figures (1) and (2), respectively. These are two parameters revealed the flow of tested powders.

$$C = 100 \times (1 - \rho B/)T) \quad (21)$$

4. Disintegration Time –

Scattering tests were performed according to the strategy described in the European Pharmacopeia guideline, dispersing tablets and capsules monograph using the Sotax DT50 dispersal apparatus (Sotax AG, Basel, Switzerland). Six pills in each case were tested simultaneously and the results were presented as a median ± standard deviation. The final point is reached when there is no debris left on the bottom of the test basket. (22)

5. Angle of Repose –

Powder flowability was also evaluated by the measurement of the angle of repose according to the European Pharmacopeia guideliànes. It was determined by allowing an excess quantity of each material (about 50 g) positioned above a fixed diameter base to drain from the container. The formation of a cone of powder on the fixed diameter base allowed the determination of the drained angle of repose. (23)

6. Spray drying-

The polymer compound as shown in Table No. 3 was used for spraying purposes. Methacrylic acid (eudragit) is dissolved in a mixture of acetone and IPA 1: 1. One the polymer was dispersed with a 1: 1 mixture of IPA and DCM. Both of these solutions were integrated and colloidal silicon dioxide was added to the concentration of 0.5% w / w. The result the mixture was stored for packaging and the spray was dried at an inlet temperature of 35 ± 3 C per an atomization pressure of 0.9 ± 0.1 bar and airflow of 40e60 cfm for joint processing polymers SD-1 to SD-6. (19)

MICROMERITIC PROPERTIES OF THE BLEND BULK DENSITY:(24)

- **Tapped density –**

The weighted mixture is transferred to the measuring cylinder and is less than 100 taps. Then the volume is marked as a trusted volume. Reliable congestion is measured using the following formula (initial weight / reliable volume).

- **Carr's index –**

It indicates compressibility of Powder. Carr's index was calculated by using the following formula.

Carrs index = (tapped density – Bulk density/tapped density)*100

- **Bulk density-**

Blend was weighed and transferred to a measuring cylinder. Then a large volume was recognized. Lots congestion is calculated using the following formula.

Mass density = Bulk powder / Volume.

- **Hausner's ratio –**

It is the number that can be correlated with the flowability of powder

Hausner's ratio = tapped density/bulk density

- **Angle of repose –**

The required amount of the mixture was taken and poured into an empty cylinder on which it was placed graph. Then the cylinder was slowly raised. Then the length and width of the pile the built is marked down. The resting angle (θ) is calculated by the formula.

Relax angle = tan (r / h)

CO-PROCESSED EXCIPIENT IN THE LITERATURE:

- **Microcrystalline cellulose (MCC) and calcium carbonate –**

Mehra et al. (1986) patent the combined excipient of microcrystalline cellulose and calcium carbonate. The jointly excised excipient was used for directly compressed production vitamin tablets. The establishment was economical and showed low sensitivity to lubricant.(25)

- **MCC and methylcellulose –**

Augello and Vladyka (1999) developed an excipient for joint processing of wet granulating MCC and methylcellulose. Begins are then less spheronizing into spheres with a smooth

uniform surface. The final product acts as a coating polymer coating to hide the complete taste of a bitter drug like ibuprofen while not having a negative effect on the bioavailability of the drug. (26)

- **MCC and mannitol-**

Slurry of MCC and mannitol were sprayed dried to spherical particulate. The composition had an improved compatibility profile, lubricant sensitivity, and ejection profile compared to the physical mixture and individual component. (27)

Limitation:

The main limitation of the excipient compound processed by sharing is the proportion of auxiliary substances in the mixture adjusted and in developing new formats, the minimum number of assistants may not be the maximum API selection and capacity of each tablet under development. Co-coated adjuvant does not have official acceptance in pharmacopeia. For this reason, a combination of binder filling will not be adopted by a combination of herbal remedies. Although the spray highlights dextrose maltose. Emdex and powdered sugar are products that have been jointly processed as components and are valid for USP / NF.(29)

ADVANTAGES OF CO-PROCESSED EXCIPIENTS: (19)

- Changes in melting profiles are less likely to occur in tablets made with direct congestion in the latter place are those made of granulations.
- The main benefit of direct pressure over wet granulation is economic from the point of view pressure requires a few units operations.
- This is very important because the official compendium now needs to be dissolved details in many solid dosage forms.
- Delivery of low volumes of very strong compounds that require pollution.
- Give one facilitator multiple tasks.
- Better purification power.
- Delivery of low volumes of very strong compounds that require pollution.

- Development of organoleptic structures

DIS-ADVANTAGES:(19)

• Special filling equipment and high-temperature processing are required.

• The process is expensive due to labor, space, special equipment of the time, and energy requirements.

• Loss of assets during various stages of processing.

• Frequency of direct producer interaction with personal product production area will be reduced.

• A large number of types of equipment are required.

• High loss of assets



Figure No. 1: Excipients' Co-Processing By Particle Agglomeration

Figure No. 2: Classification of Excipient

CO-PROCESSING METHODOLOGY(32)

Excipient selection based on material characteristics

↓

Selection of proportion of excipients

↓

Homogenous dispersion or solution

↓

Co-drying

↓

Co -Processed excipient

CONCLUSION:

Completion From the current work involving supporters of MCC, Mannitol and Dehydrated banana powder is higher than a mixture of MCC, Mannitol, and Banana powder dehydrated. Enhanced collectively analyzed excipients can be used in future Development studies novel Strong volume forms. The current work involves testing with direct pressure of the performance of the new Co-operatively Consolidated Assistant (Cop AA-MCC) compared to a co-operatively negotiated transaction Excipients Collectively excised excipients have improved performance properties using eudragit RSPO and ethyl cellulose NC50 without any chemical changes in a spray formulation. Improved collectively excised excipient has shown a good ongoing drug release area and could be another way to do so. Overcome problems associated with only one polymer.

REFERENCES:

1. https://www.google.com/url?sa=t&source=web&rct=j&url=https://pharmacy.dypvp.edu.in/pharmaceutical-resonance/downloads/original-research-articles/current-issue/0007-Sunil-Aute.pdf&ved=2ahUKEwjP2rWg8tL0Ah
2. https://www.researchgate.net/publication/331806143_Co-Processed_Excipients_New_Era_in_Pharmaceuticals
3. https://www.researchgate.net/publication/320446757_Co_Processed_Excipients_for_Tabletting_Review_Article
4. https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.researchgate.net/publication/319047248_A_novel_co-processed_directly_compressible_release-retarding_polymer_In_vitro_solid_state_and_in_vivo_evaluation&ved=2ahUKEwiW_M387tL0AhXVyzgGHS2nA4AQFnoECAYQAQ&usg=AOvVaw2Cjui-Uhg-Knm1Ck4JnwT9)
5. York, P. 1992. Crystal engineering and particle Design for the powder compaction process Drug. Dev. And Ind. Pharm. 18, 677-
6. Le Hir, A. Formespharmaceutiques: Comprimés. In Abrégés de PharmacieGalénique; Masson: Paris, France, 1992.
7. Augsburger, L.L.; Hoag, S.W. Pharmaceutical Dosage Forms. Tablets, 3rd ed.; Informa Healthcare: New York, NY, USA, 2008; ISBN978-0-8493-9014-2.
8. Schmidt PC, Rubensdorfer CJ. Evaluation of ludipress as a multipurpose excipients for direct compression part I: Powder characteristics and tableting properties. Drug Dev Ind Pharm 1994;20:2899-925.8
9. Pakhale BA, Shinkar DM, Saudagar RB. Co-processed excipient: an overview. World J Pharm Res 2014;4:454-69.
10. Atul P, Subrata K, Ganga S. A review on co-processed excipients: a novel approach in formulation development. IJRAPI 2013;3:25-41
11. Patel SS, Patel NM. Development of directly compressible coprocessed excipients for dispersible tablets using 32 full factorial design. Int J Pharmacy Pharm Sci, 2009; 1:125-148
12. Steinberg M, Blecher L. and Mercill A. From Inactive Ingredients to Pharmaceutical Excipients. Pharm. Technol..2001; 25 (7): 62-64
13. Shangraw RF, Wallace JW and Bowes FM. Morphology and functionality in Tablet Excipients for Direct Compression. Pharm Technol, 11, 1987, 136-143
14. Reimerdes D. The near future of tablet excipients. Manufacturing Chemist, 64(7), 1993, 14-15 .

15. Chowdary KPR, Franklin Israel S and Satyanarayana AR.Preparation, Characterization and Evaluation of Starch - PEG1500 Co-Processed Excipient as Directly Compressible Vehicle In Tablet Formulations. International Journal of Comprehensive Comprehensive Pharmacy, 11(4), 2012, 1-4.
16. Shirwaikar AA. Novel coprocessed excipients of Mannitol and microcrystalline cellulose for preparing fast dissolving tablets of glipizide. Indian J Pharm Sci, 69, 2007, 633-9.
17. https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.researchgate.net/publication/330193672_COPROCESSED_EXCIPIENTS_AN_OVERVIEW&ved=2ahUKEwilae_9L0AhVfwTgGHYD3CBsQFnoECAMQAQ&usg=AOvVaw2HaWd63sKuJwhrkeKyHI2S
18. Ajay SubhashChougule, Amrita Dikpati and TusharTrimbake.Formulation Development Techniques of Co-processed Excipients. Journal of Advanced Pharmaceutical Sciences 2(2),2012, 231-249.12
19. https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.researchgate.net/publication/330193672_CO-PROCESSED_EXCIPIENTS_AN_OVERVIEW&ved=2ahUKEwilkuae_9L0AhVfwTgGHYD3CBsQFnoECAMQAQ&usg=AOvVaw2HaWd63sKuJwhrkeKyHI2S
20. BASF, Ludipress®Product Information. Available online: Https://Pharmaceutical.Basf.Com/Global/En/Drug-Formulation/Products/Ludipress.Html (accessed on 5 March 2020).
21. Bulk density and tapped density of powders (monograph 2.9.34). In European Pharmacopeia; European Directorate for the Quality of Medicines &HealthCare, Council of Europe: Strasbourg, France, 2019; pp. 384–387.
22. Powder flow (monograph 2.9.36). In European Pharmacopeia; European Directorate for the Quality of Medicines &HealthCare, Council of Europe: Strasbourg, France, 2019; pp. 387–391.
23. Disintegration of tablets and capsules (monograph 2.9.34). In European Pharmacopeia; European Directorate for the Quality of Medicines &HealthCare, Council of Europe: Strasbourg, France, 2019; pp. 323–325.
24. Reddy LH, Ghosh Bijaya, Rajneesh; Fast Dissolving Drug Delivery Systems: A Review of the Literature. Ind J Pharm Sci., 2002; 64(4):331-336.
25. Mehra DK, West KP, Wiggins DJ. Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation. EP0193984; 1986
26. Augello M, Vladyka RS, Dell SM. Taste masked pharmaceutical composition. US5904937; 1999.
27. . Li J, Carlin B, Ruszkay T. Co-processed microcrystalline andsugar alcohol as an excipient for tablet formulations. US20080131505; 2008.
28. Gupta Piyush, Nachaegari Satish K, Bansal Arvind K. Improved Excipient Functionality by Co-processing and. pp.109-112.
29. Shangraw RF, Wallace JW and Bowes FM. Morphology and functionality in Tablet Excipients for Direct Compression. Pharm Technol, 1987; 11: 136-143.
30. https://images.app.goo.gl/YW5KmT3dTsEcUpKV7 33
31. https://images.app.goo.gl/S6NeuSGarvgKd5yM6 34.
32. https://images.app.goo.gl/eF574Yj3gD84MDFF